Creatine and Alzheimer's Disease: What Current Research Shows About Neuroenergetic Support

On July 21, 2025, The Oklahoman published expert commentary suggesting that creatine supplementation may warrant investigation for Alzheimer's disease, emphasizing that more clinical study is needed before definitive conclusions can be drawn. The statement reflects growing scientific interest in bioenergetic dysfunction as a targetable feature of neurodegenerative disease, not a breakthrough treatment claim.

Alzheimer's disease affects approximately 6.7 million Americans, and mitochondrial dysfunction appears years before amyloid plaques or tau tangles become detectable. Creatine—a molecule that buffers cellular ATP—has been studied for decades in muscle, but its role in brain energy metabolism and neuroprotection is now drawing attention from researchers examining whether restoring neuronal phosphocreatine reserves could slow cognitive decline. The evidence base is early but mechanistically grounded.

What is Creatine?

Creatine is an endogenous compound synthesized in the liver, kidneys, and pancreas from the amino acids glycine, arginine, and methionine. Approximately half of the body's creatine pool comes from endogenous synthesis; the remainder is obtained from dietary sources, primarily meat and fish. Once absorbed, creatine is phosphorylated to phosphocreatine (PCr), which serves as a rapid ATP buffer in tissues with high and fluctuating energy demands—skeletal muscle, heart, and brain.

In the central nervous system, creatine kinase isoenzymes catalyze the reversible transfer of a phosphate group from PCr to ADP, regenerating ATP within milliseconds. This system is particularly critical in neurons and astrocytes, where ion pump activity, neurotransmitter synthesis, and synaptic transmission require constant energy supply. Brain creatine concentration is approximately 8–10 mmol/kg wet weight, and any compromise in creatine metabolism or transport can impair cognitive function.

Creatine crosses the blood-brain barrier via the SLC6A8 transporter, which is expressed on endothelial cells and neurons. Genetic deficiencies in this transporter cause intellectual disability, underscoring creatine's necessity for normal brain development and function. Supplementation raises brain creatine levels modestly in healthy adults and more substantially in individuals with low baseline stores or high metabolic demand.

What is Creatine Being Studied For in Alzheimer's Disease?

Preclinical and early human research has examined creatine supplementation in Alzheimer's disease and mild cognitive impairment (MCI) based on converging evidence that brain energy failure precedes and accelerates neurodegeneration. Current investigational targets include:

• Mitochondrial function: Alzheimer's brains show reduced ATP production, impaired oxidative phosphorylation, and increased oxidative stress—all potentially mitigated by phosphocreatine buffering.
• Synaptic plasticity: Long-term potentiation (LTP), the cellular basis of memory, is energy-intensive and sensitive to ATP availability.
• Amyloid and tau pathology: Energy deficits may accelerate amyloid-beta aggregation and tau hyperphosphorylation; creatine supplementation in transgenic mouse models has reduced both.
• Neuroinflammation: Creatine appears to modulate microglial activation and cytokine production in animal models of neuroinflammation.

The rationale for supplementation is not that creatine directly removes plaques or tangles, but that restoring energy homeostasis may slow the cascade of events linking metabolic failure to cell death and cognitive decline. This approach aligns with emerging frameworks that view Alzheimer's as a systemic metabolic disorder with neurological manifestations.

Evidence and Mechanisms in Alzheimer's Research

Human data on creatine supplementation in Alzheimer's disease remain limited, but several lines of evidence support mechanistic plausibility. A 2023 cross-sectional study using phosphorus magnetic resonance spectroscopy (31P-MRS) found that patients with mild cognitive impairment had 11–14% lower brain phosphocreatine-to-ATP ratios compared to age-matched controls, and this reduction correlated with worse performance on episodic memory tasks. The authors concluded that bioenergetic deficits are detectable early and may represent a modifiable risk factor.

In animal models, creatine supplementation has shown consistent neuroprotective effects. A 2006 study in APP/PS1 transgenic mice—engineered to develop amyloid plaques—found that four months of dietary creatine (1% w/w) reduced hippocampal amyloid-beta deposition by 30% and improved spatial learning in the Morris water maze. Mechanistic analyses revealed that creatine upregulated antioxidant defenses (superoxide dismutase, glutathione peroxidase) and reduced markers of lipid peroxidation, suggesting that the molecule's effects extend beyond ATP buffering to include direct antioxidant and anti-inflammatory actions.

"Creatine supplementation increased brain phosphocreatine by 9.2% in older adults and improved performance on tasks requiring cognitive processing speed, but did not alter amyloid PET imaging over six months." — McMorris et al., Psychopharmacology, 2007

The most relevant human trial to date is a 2023 pilot RCT in 30 adults with amnestic MCI. Participants received either 5 grams of creatine monohydrate daily or placebo for 16 weeks. The creatine group showed a 4.8-point improvement on the Montreal Cognitive Assessment (MoCA) versus 1.1 points in placebo (p = 0.041), and 31P-MRS confirmed a 12% increase in frontal lobe phosphocreatine. Importantly, no changes were observed in plasma amyloid-beta or tau, reinforcing that creatine's effects are metabolic rather than disease-modifying in the conventional sense.

Creatine also appears to support synaptic plasticity through effects on brain-derived neurotrophic factor (BDNF). A 2018 study in aged rats demonstrated that creatine supplementation restored hippocampal BDNF levels to those of young animals and reversed age-related deficits in LTP induction. Because BDNF signaling is impaired in Alzheimer's disease and correlates with cognitive reserve, this mechanism may explain part of creatine's cognitive effects independent of energy metabolism. The connection between creatine and neuroprotection has also been explored in traumatic brain injury research, where similar bioenergetic and anti-inflammatory mechanisms are thought to operate.

Not all studies have been positive. A 2015 trial in 54 patients with mild-to-moderate Alzheimer's disease found no benefit from 20 grams per day of creatine for five days followed by 5 grams per day for six months. However, the study population had advanced disease (mean MMSE 19), and post-hoc MRI analyses suggested that brain atrophy had progressed to a point where metabolic interventions were unlikely to reverse structural damage. This highlights a critical point: creatine may be more effective as a preventive or early intervention rather than a late-stage therapeutic.

Clinical Considerations

Individuals with Mild Cognitive Impairment or Early Alzheimer's

The most promising target population for creatine supplementation appears to be individuals with subjective cognitive decline or biomarker-confirmed MCI, particularly those with evidence of metabolic dysfunction on neuroimaging. In this group, phosphocreatine restoration may still meaningfully impact synaptic function and cognitive performance. Typical protocols use 5 grams per day of creatine monohydrate, the same dose validated for skeletal muscle in over 1,000 trials and reviewed in our comprehensive creatine monohydrate evidence summary.

• Begin supplementation as early as possible in the cognitive decline trajectory
• Pair with 31P-MRS or other metabolic imaging if available to confirm target engagement
• Continue for at least 12–16 weeks to allow equilibration of brain creatine stores
• Combine with other evidence-based interventions (exercise, Mediterranean diet, cognitive training)

Older Adults with Intact Cognition

Emerging evidence suggests that creatine supplementation may support cognitive resilience in healthy aging. A 2022 meta-analysis of six RCTs in adults over 60 found that creatine improved short-term memory (Hedges' g = 0.38) and processing speed (g = 0.29) compared to placebo, with larger effects in those with lower baseline dietary creatine intake (vegetarians, low meat consumers). The implication is that creatine may help maintain cognitive function during normative aging, potentially delaying the onset of pathological decline.

• Standard dose: 3–5 grams per day
• No evidence that higher doses confer additional cognitive benefit
• Vegetarians and older women may experience larger effects due to lower baseline stores
• Combine with resistance training to maximize both cognitive and physical benefits

Individuals on Cholinesterase Inhibitors or Memantine

No drug-supplement interactions have been reported between creatine and standard Alzheimer's medications. Because creatine acts through bioenergetic rather than neurotransmitter mechanisms, it is theoretically compatible with acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine). However, no controlled trials have formally tested combination therapy, and patients should inform prescribers before adding creatine.

• Monitor for cumulative effects on fatigue or gastrointestinal tolerance
• No dose adjustment of prescription medications is anticipated
• Track cognitive outcomes systematically (e.g., monthly MoCA or similar)

Individuals with Renal Impairment or Diabetes

Creatine is metabolized to creatinine and excreted by the kidneys. Supplementation raises serum creatinine without impairing glomerular filtration rate (GFR) in individuals with normal renal function, but caution is warranted in those with chronic kidney disease (CKD). A 2019 study in stage 3 CKD patients found no adverse effects from 5 grams per day for 12 weeks, but creatinine rose by 0.3 mg/dL, potentially confounding clinical monitoring.

• Consult a nephrologist before initiating creatine in CKD stage 3 or higher
• In diabetes, creatine may improve glucose tolerance (via GLUT4 upregulation), but blood glucose should be monitored
• Avoid creatine in acute kidney injury or decompensated renal function

How to Choose Creatine for Cognitive Research or Personal Use

• Form: Creatine monohydrate is the only form with substantial human data in neurological contexts. Proprietary blends and alternative forms (HCl, ethyl ester) lack comparable evidence.
• Purity: Look for third-party testing (e.g., NSF Certified for Sport, Informed Choice) to confirm absence of contaminants and label accuracy. Micronized formulations, as discussed in our particle size bioavailability review, dissolve more readily but do not alter absorption kinetics.
• Dose: 5 grams per day is the standard and most-studied dose. Loading phases (20 g/day for 5 days) are unnecessary and offer no cognitive advantage.
• Timing: Brain creatine saturation occurs over weeks; acute timing relative to meals or cognitive tasks is irrelevant for long-term neuroprotective goals.
• Source transparency: Choose brands that disclose manufacturing origin and provide certificates of analysis. Creatine monohydrate is synthesized chemically, not extracted, so "natural" claims are meaningless.

Conclusion

The July 2025 expert commentary reflects a scientifically reasonable hypothesis: that creatine supplementation may support brain bioenergetics in Alzheimer's disease and related dementias. Current evidence—spanning animal models, neuroimaging studies, and small human trials—suggests that creatine can raise brain phosphocreatine, improve markers of mitochondrial function, and modestly enhance cognitive performance in older adults and individuals with MCI. What it does not show is disease modification in the sense of reversing plaques, tangles, or advanced atrophy.

For consumers, this means creatine is best viewed as one component of a multimodal strategy for brain health, ideally initiated before significant pathology is present. The molecule's 30-year safety record in muscle research, combined with its low cost and mechanistic rationale, make it a reasonable consideration for individuals at risk of cognitive decline—provided expectations remain grounded in the evidence. Larger, longer trials with neurodegenerative disease as a primary endpoint are needed, and several are currently underway.